HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41

Journal of Immunology

Volumn 176, Issue 11, 2006, Pages 6900-6905

  Cole, Amy L ^a   Yang, Otto O ^b   Warren, Andrew D ^a   Waring, Alan J ^b   Lehrer, Robert I ^b   Cole, Alexander M ^a,c  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CATION; CD4 ANTIGEN; DEFENSIN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; RETROCYCLIN; RETROCYCLIN 101; THETA DEFENSIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; VIRUS ENVELOPE; VIRUS RESISTANCE;

EID: 33646873341     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.11.6900     Document Type: Article

References (30)

1. Liu, L., C. Zhao, H. H. Q. Heng, and T. Ganz. 1997. The human β-defensin-1 and α-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics 43: 316-320.
2. Lehrer, R. I. 2004. Primate defensins. Nat. Rev. Microbiol. 2: 727-738.
3. Selsted, M. E., and A. J. Ouellette. 2005. Mammalian defensins in the antimicrobial immune response. Nat. Immunol. 6: 551-557.
4. Tang, Y. Q., J. Yuan, G. Osapay, K. Osapay, D. Tran, C. J. Miller, A. J. Ouellette, and M. E. Selsted. 1999. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated α-defensins. Science 286: 498-502.
5. Tran, D., P. A. Tran, Y. Q. Tang, J. Yuan, T. Cole, and M. E. Selsted. 2002. Homodimeric θ-defensins from rhesus macaque leukocytes: isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic peptides. J. Biol. Chem. 277: 3079-3084.
6. Leonova, L., V. N. Kokryakov, G. M. Aleshina, T. Hong, T. Nguyen, C. Zhao, A. J. Waring, and R. I. Lehrer. 2001. Circular minidefensins and posttranslational generation of molecular diversity. J. Leukocyte Biol. 70: 461-464.
7. Cole, A. M., T. Hong, L. M. Boo, T. Nguyen, C. Zhao, G. Bristol, J. A. Zack, A. J. Waring, O. O. Yang, and R. I. Lehrer. 2002. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA 99: 1813-1818.
8. Nguyen, T. X., A. M. Cole, and R. I. Lehrer. 2003. Evolution of primate θ-defensins: a serpentine path to a sweet tooth. Peptides 24: 1647-1654.
9. Wang, W., A. M. Cole, T. Hong, A. J. Waring, and R. I. Lehrer. 2003. Retrocyclin, an antiretroviral θ-defensin, is a lectin. J. Immunol. 170: 4708-4716.
10. Wang, W., S. M. Owen, D. L. Rudolph, A. M. Cole, T. Hong, A. J. Waring, R. B. Lal, and R. I. Lehrer. 2004. Activity of α- and θ-defensins against primary isolates of HIV-1. J. Immunol. 173: 515-520.
11. Owen, S. M., D. L. Rudolph, W. Wang, A. M. Cole, A. J. Waring, R. B. Lal, and R. I. Lehrer. 2004. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 20: 1157-1165.
12. Venkataraman, N., A. L. Cole, P. Svoboda, J. Pohl, and A. M. Cole. 2005. Cationic polypeptides are required for Anti-HIV-1 activity of human vaginal fluid. J. Immunol. 175: 7560-7567.
13. Peschel, A. 2002. How do bacteria resist human antimicrobial peptides? Trends Microbiol. 10: 179-186.
14. Gunn, J. S., S. S. Ryan, J. C. Van Velkinburgh, R. K. Ernst, and S. I. Miller. 2000. Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar typhimurium. Infect. Immun. 68: 6139-6146.
15. Gunn, J. S. 2001. Bacterial modification of LPS and resistance to antimicrobial peptides. J. Endotoxin Res. 7: 57-62.
16. Ernst, R. K., T. Guina, and S. I. Miller. 2001. Salmonella typhimurium outer membrane remodeling: role in resistance to host innate immunity. Microbes Infect. 3: 1327-1334.
17. Münk, C., G. Wei, O. O. Yang, A. J. Waring, W. Wang, T. Hong, R. I. Lehrer, N. R. Landau, and A. M. Cole. 2003. The θ-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res. Hum. Retroviruses 19: 875-881.
18. Yasin, B., W. Wang, M. Pang, N. Cheshenko, T. Hong, A. J. Waring, B. C. Herold, E. A. Wagar, and R. I. Lehrer. 2004. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J. Virol. 78: 5147-5156.
19. Baldwin, C. E., R. W. Sanders, Y. Deng, S. Jurriaans, J. M. Lange, M. Lu, and B. Berkhout. 2004. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78: 12428-12437.
20. Nameki, D., E. Kodama, M. Ikeuchi, N. Mabuchi, A. Otaka, H. Tamamura, M. Ohno, N. Fujii, and M. Matsuoka. 2005. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J. Virol. 79: 764-770.
21. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72: 986-993.
22. Trkola, A., S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. Xu, L. Wojcik, J. Tagat, et al. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 99: 395-400.
23. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46: 1896-1905.
24. Nei, M., and T. Gojobori. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3: 418-426.
25. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, et al. 1996. Identification of a major coreceptor for primary isolates of HIV-1. Nature 381: 661-666.
26. Philpott, S. M. 2003. HIV-1 coreceptor usage, transmission, and disease progression. Curr. HIV Res. 1: 217-227.
27. Marozsan, A. J., S. E. Kuhmann, T. Morgan, C. Herrera, E. Rivera-Troche, S. Xu, B. M. Baroudy, J. Strizki, and J. P. Moore. 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338: 182-199.
28. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
29. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
30. Lee, W. R., X. F. Yu, W. J. Syu, M. Essex, and T. H. Lee. 1992. Mutational analysis of conserved M-linked glycosylation sites of human immunodeficiency virus type 1 gp41. J. Virol. 66: 1799-1803.